Mepolizumab Safety and Efficacy in RealWorld Clinical Practice REALITIA Study Mepolizumab Safety and Efficacy in RealWorld Clinical Practice REALITIA Study cont Effect of Dupilumab on Lung Function in Uncontrolled ModeratetoSevere Allergic Asthma ID: 775164
Download Presentation The PPT/PDF document " Asthma Introduction New Data on Biologi..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Asthma
Slide2Slide3Introduction
Slide4New Data on Biologic Therapy in Severe Asthma
Slide5Mepolizumab Safety and Efficacy in Real-World Clinical Practice: REALITI-A Study
Slide6Mepolizumab Safety and Efficacy in Real-World Clinical Practice: REALITI-A Study (cont)
Slide7Effect of Dupilumab on Lung Function in Uncontrolled Moderate-to-Severe Allergic Asthma
Slide8Effect of Dupilumab on Exacerbation Rate
Slide9Effect of Dupilumab on Lung Function in Uncontrolled Moderate-to-Severe Allergic Asthma
Slide10Effect of Dupilumab on Lung Function in Uncontrolled Moderate-to-Severe Allergic Asthma (cont)
Slide11Omalizumab and Mepolizumab vs No Biologic in the Treatment in Severe Asthma
Slide12Omalizumab and Mepolizumab vs No Biologic in the Treatment of Severe Asthma (cont)
Slide13Role of Biomarkers in the Management of Severe Asthma
Slide14Use of Biomarkers in Patients With Severe Asthma Can Help Extend Pharmacologic Management
Slide15Severe Concordant Eosinophilic Asthma and IgE Status
Slide16Severe Concordant Eosinophilic Asthma and IgE Status (cont)
Slide17T2-Biomarker in Severe Asthma: UKSAR
Slide18T2-Biomarker in Severe Asthma: UKSAR (cont)
Slide19Clinical Response to Benralizumab in Patients With Severe Asthma Eosinophilic Phenotypes
Slide20Clinical Response to Benralizumab in Patients With Severe Asthma Eosinophilic Phenotypes (cont)
Slide21Severe Asthma Phenotypes: T2 High and T2 Low
Slide22Severe Asthma Phenotypes: T2 High and T2 Low (cont)
Slide23New Data on Biologic Therapy for Severe Asthma and Comorbidities and Summary
Slide24Dupilumab in Severe Chronic Rhinosinusitis With Nasal Polyps With/Without NSAID-ERD
Slide25Dupilumab in Severe Chronic Rhinosinusitis With Nasal Polyps With/Without NSAID-ERD (cont)
Slide26Dupilumab in Patients with Severe Chronic Rhinosinusitis With Nasal Polyps And NSAID-ERD
Slide27Dupilumab in Patients with Severe Chronic Rhinosinusitis With Nasal Polyps and NSAID-ERD (cont)
Slide28Fezakinumab: Novel Anti-IL-22 Antibody Potential Role in Asthma
Slide29Efficacy of Omalizumab in Patients With Severe Asthma and Multiple Allergic Comorbidities
Slide30Efficacy of Omalizumab in Patients With Severe Asthma and Multiple Allergic Comorbidities (cont)
Slide31Summary
Slide32Concluding Remarks
Slide33Abbreviations
Slide34Abbreviations (cont)
Slide35Abbreviations (cont)